Barclays Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €51.00 Price Target

Share on StockTwits

Barclays set a €51.00 ($59.30) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other research analysts have also recently issued reports about the company. Deutsche Bank set a €65.00 ($75.58) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, July 31st. DZ Bank reissued a buy rating on shares of Fresenius SE & Co KGaA in a report on Wednesday, July 31st. HSBC set a €52.00 ($60.47) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Thursday. Jefferies Financial Group set a €43.00 ($50.00) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. set a €58.40 ($67.91) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Fresenius SE & Co KGaA currently has a consensus rating of Buy and a consensus price target of €57.93 ($67.36).

Shares of FRA FRE opened at €43.37 ($50.42) on Friday. The business has a fifty day moving average of €43.63 and a two-hundred day moving average of €46.49. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: If I purchase shares through a brokerage account, am I the holder of record?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.